Series C+ · 2026-10-23 · Healthcare

Pathos AI Inc. raises $237.0M

AI Score

Amount

$237.0M

Round

Series C+

Lead

Bristol Myers Squibb Co.

—

Why it matters: The round shows pharma companies funding AI drug discovery platforms directly, with Bristol Myers Squibb leading and gaining access to Foundry and licensed patient data.

Pathos AI raised $237 million in a Series E round at a $3 billion valuation, led by Bristol Myers Squibb with returning backers including AstraZeneca.

Participants:: AstraZeneca plc, NEA, General Atlantic
Source:: SiliconANGLE ↗ · Midu summary

Deal Dossier PRO

Pro feature

Deal Dossier for Pathos AI Inc.

Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.

Generate dossier — Pro

Already Pro? Sign in · See plans

Figures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).

Recent Healthcare rounds

Browse all deals in the funding database →

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

Midu WeeklyMondays · funding trends and top roundsSee a sample issue →SF WeeklyFridays · San Francisco startups, rounds and eventsSee a sample issue →

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing